Walleye Capital LLC
Institutional investor · Portfolio as of Q4 2019
Top Holdings1,722 positions
ABBVIE INC | 300,100 | $26.6M | 1.7% | — | — | — | Increased — |
AXSOME THERAPEUTICS INC | 170,268 | $17.6M | 1.1% | $103.36 | 0.00% | 1 qtr | New 65 |
IQVIA HLDGS INC | 110,100 | $17M | 1.1% | — | — | — | Increased — |
CYPRESS SEMICONDUCTOR CORP | 727,918 | $17M | 1.1% | — | — | 1 qtr | New 64 |
WABCO HLDGS INC | 110,884 | $15M | 1.0% | — | — | 1 qtr | New 55 |
ZAYO GROUP HLDGS INC | 432,147 | $15M | 1.0% | — | — | 1 qtr | New 55 |
| 912,836 | $12.4M | 0.8% | — | — | 1 qtr | New 54 | |
MELLANOX TECHNOLOGIES LTD | 101,868 | $11.9M | 0.8% | — | — | 1 qtr | New 54 |
ALLERGAN PLC | 61,711 | $11.8M | 0.8% | — | — | 1 qtr | New 54 |
BREAD FINANCIAL HOLDINGS INC | 85,400 | $9.6M | 0.6% | — | — | — | Increased — |
AMGEN INC | 38,200 | $9.2M | 0.6% | — | — | — | Decreased — |
WELLCARE HEALTH PLANS INC | 26,882 | $8.9M | 0.6% | — | — | 1 qtr | New 54 |
ACACIA COMMUNICATIONS INC | 127,852 | $8.7M | 0.6% | — | — | 3 qtrssince 2019-Q2 | Increased 63 |
MCDONALDS CORP | 41,800 | $8.3M | 0.5% | — | — | — | Increased — |
JOHNSON & JOHNSON | 56,500 | $8.2M | 0.5% | — | — | — | Decreased — |
ADVANCED DISP SVCS INC DEL | 236,366 | $7.8M | 0.5% | — | — | 1 qtr | New 53 |
MEDICINES CO | 90,809 | $7.7M | 0.5% | — | — | 1 qtr | New 53 |
CONSTELLATION BRANDS INC | 40,100 | $7.6M | 0.5% | — | — | — | Increased — |
GRUBHUB INC | 154,400 | $7.5M | 0.5% | — | — | — | Increased — |
ZOETIS INC | 55,300 | $7.3M | 0.5% | — | — | — | Decreased — |
Walleye Capital LLC manages $1.5B across 1722 positions as of Q4 2019. Top holdings: ABBV calls (1.7%), AXSM (1.1%), IQV calls (1.1%). Fund DNA: Diversified Scout. HoldingsIntel Score: 2.5/5.0.
Active quarter - 363 new positions, 207 exits, 130 increased. Top move: AXSM (NEW, conviction 65). Portfolio: $1.5B across 1722 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR